IP Library Granted Patent US 7,456,317
Granted Patent B2
US 7,456,317 · App. 11/565,451 · Granted Nov 25, 2008

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Assignee: Auspex Pharmaceuticals
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,317
App. No.
11/565,451
Granted
Nov 25, 2008
Kind
B2
Abstract

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Claims (11)

1. A compound having the structural formula:

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 .

3. The pharmaceutical composition of claim 2 , wherein said composition is suitable for oral, parenteral, or intravenous infusion administration.

4. The pharmaceutical composition of claim 3 , wherein said composition suitable for oral administration comprises a tablet or a capsule.

5. The pharmaceutical composition of claim 2 , wherein said compound of claim 6 is administered in a total daily dose of 0.5 milligram to 400 milligram.

6. The compound of claim 1 , wherein said compound is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.

7. The compound of claim 1 , wherein said compound is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.

8. The compound of claim 1 , wherein said compound is a hydrochloride salt.

9. The compound of claim 8 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.

10. The compound of claim 8 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2021
From: AUSPEX PHARMACEUTICALS, INC.
To: ACADIA PHARMACEUTICALS INC.
Reel/Frame 056758/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2007
From: GANT, THOMAS G.; SARSHAR, SEPEHR
To: AUSPEX PHARMACEUTICALS, INC.
Reel/Frame 019006/0859 →
Continuity (3)
Provisional Application 6074131500 · Dec 1, 2005
Provisional Application 6084136600 · Aug 30, 2006
Related Publication 20070149622A1 · Jun 28, 2007